Philadelphia, PA-- (September 24, 2012) – Wolters Kluwer Health is pleased to announce the publication of Cardiovascular Endocrinology, a new online, peer-reviewed journal committed to fostering effective collaboration between cardiologists and endocrinologists in addressing diabetes, hypertension, dyslipidemia, and related diseases and conditions. Lippincott Williams & Wilkins (LWW), a part of Wolters Kluwer Health, is the publisher of record for the journal.
"The growing global prevalence of obesity-associated diabetes, hypertension, and dyslipidemia makes it imperative that cardiologists, endocrinologists, and others have a forum for new treatment and therapeutic developments. The new journal aspires to provide this forum by ensuring that researchers and clinicians have access to research and opinion that bridges these disciplines," said Andrew J. Krentz, Editor-in-Chief of Cardiovascular Endocrinology.
"We're pleased to announce the official launch of Cardiovascular Endocrinology journal that brings together these specialists to focus research on some of the world's most widespread and intractable health problems," said Jayne Marks, Vice President Publishing, Wolters Kluwer Health Medical Research. "With LWW's well-regarded portfolio in both cardiology and endocrinology combined with our strong global reach, we're encouraged about the contributions the journal will bring to these disciplines to improve patient care."
Highlights of the inaugural issue include original research on a potential role for natriuretic peptide therapy in human cardiac ischemia and a review article on the role of melatonin in hypertension. In addition, subscribers have an opportunity to earn CME credit—provided by the Lippincott CME Institute—through LWW's XtraCredit mobile application.
The editorial board encourages prospective authors to submit original manuscripts for publication in Cardiovascular Endocrinology. For more information, including specific instructions and guidelines, visit the journal's website at http://www.cardiovascularendocrinology.com.
The online quarterly journal is available to individual subscribers via LWW's online journal platform and institutional access is provided through OvidSP, the world's leading medical research platform from Ovid, also a part of Wolters Kluwer Health.
About Cardiovascular Endocrinology
Cardiovascular Endocrinology publishes peer-reviewed research in vascular disease, endocrinology, and metabolism. Particular emphasis is placed on studies that illuminate the interaction between these disciplines. The journal serves as a single resource for the cardiology, endocrinology and metabolism research, and clinical communities. High quality state-of-the-art reviews, invited editorials, and expert commentaries place original articles in context at the interface of basic and clinical research.
About Wolters Kluwer Health
Wolters Kluwer Health (Philadelphia, PA) is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Lippincott Williams & Wilkins, Ovid®, Medknow, UpToDate®, Medi-Span®, Facts & Comparisons®, Pharmacy OneSource®, Lexicomp® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer has 2011 annual revenues of €3.4 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.
Journal
Cardiovascular Endocrinology